Market Access

  • Home
  • Services
  • Market Access

Value based health care is gaining traction to reduce the gap between the rise in demand for new interventions and the limited financial resources available.

The critical appraisal of cost-effectiveness by health care payers and their nominated agencies have applied pressure on health care developers to review health economics and outcomes research (HEOR) earlier in their clinical development plans to gain optimal pricing and reimbursement.

market access

At Axcellant, our team have supported organisations navigate through the UK National Institute of Clinical Excellence (NICE) Health Technology Assessment (HTA). We have also supported pricing and reimbursement research commissioned by the French Ministry of Health and Social Affairs and also modelling for agencies in the US and Asia.



Key Considerations for Initiating a Clinical Trial: A Comprehensive Guide

Initiating a clinical trial is akin to embarking on a voyage of discovery in the realm of medicine. This journey,…

Completion of a significant clinical study

Our team at Axcellant is proud to announce the completion of a significant Post-Market Clinical Follow-up study. This study was…

Unveiling Real-World Evidence in Clinical Trials

In the ever-evolving realm of pharmaceuticals and healthcare, a remarkable transformation is afoot - one that's reshaping the way we…